<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-OLL25923-C92-08-HW8"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S2276 IS: Eliminating Thickets to Increase Competition Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-07-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 2276</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250715">July 15, 2025</action-date><action-desc><sponsor name-id="S422">Mr. Welch</sponsor> (for himself, <cosponsor name-id="S399">Mr. Hawley</cosponsor>, and <cosponsor name-id="S311">Ms. Klobuchar</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSJU00">Committee on the Judiciary</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To address patent thickets.</official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause"><section id="id8d227b0b6321441987fe621316f00b21" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Eliminating Thickets to Increase Competition Act</short-title></quote> or the <quote><short-title>ETHIC Act</short-title></quote>.</text></section><section id="S1"><enum>2.</enum><header>Addressing patent thickets</header><subsection id="ida9a66690a66d4c9d8486845ef2c9945d"><enum>(a)</enum><header>Limit on number of patents per patent group that may be asserted in action for infringement</header><text>Section 271(e) of title 35, United States Code, is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id6FC8A7E4C29C47B7B4DFF88610B361AE"><paragraph id="idc20fad684c194187b6d2baa9fbb94587" indent="up1"><enum>(7)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="idde1fad8be8ad48df84e9c1509d683ee1"><enum>(A)</enum><text>A person who brings an action for infringement of a patent under this section against a party described in subparagraph (B) may assert in the action not more than one patent per Patent Group.</text></subparagraph><subparagraph id="id3813f9e6648b4c54b7775f0a050eef43" indent="up1"><enum>(B)</enum><text>A party described in this subparagraph is—</text><clause commented="no" display-inline="no-display-inline" id="id5545630a17bc4435a63e567a1288d251"><enum>(i)</enum><text>a person who—</text><subclause commented="no" display-inline="no-display-inline" id="id844969722bdd4d57960a11601952f1fb"><enum>(I)</enum><text>submits an application for approval of a drug under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), or is a holder of such an approved application; or</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id2cac6f5e14de4b8cbaf841037c722c9c"><enum>(II)</enum><text>submits an application for licensure of a biological product under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>), or is a holder of such a licensure; or</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="idb1682aa5d78c46149f16c4f847e02600"><enum>(ii)</enum><text>a person making, using, selling, offering for sale, introducing or delivering into interstate commerce, or importing—</text><subclause commented="no" display-inline="no-display-inline" id="id2e7cf738f31349b5bf723a98d9bffba4"><enum>(I)</enum><text display-inline="yes-display-inline">a drug approved pursuant to an application under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>); or</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id09accd6570dc4ff48b842b2e584289c4"><enum>(II)</enum><text>a biological product licensed under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>).</text></subclause></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" indent="up1" id="id059ad6fa5673408bb19ddd3799723a38"><enum>(C)</enum><text>A person who brings an action described in subparagraph (A) asserting a patent against a party may not bring any additional actions described in that subparagraph asserting a patent in the same Patent Group against that party.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" indent="up1" id="id7ef8acc38cc24aa784f5e9282f227814"><enum>(D)</enum><clause commented="no" display-inline="yes-display-inline" id="id5f8514bea5ba4131b6f9c7ca1775ef7b"><enum>(i)</enum><text>For purposes of this paragraph, the term <term>Patent Group</term> means 2 or more commonly owned patents or applications that—</text><subclause commented="no" display-inline="no-display-inline" indent="up1" id="idb25f8b13a2ea4bb4b099ed40a2b7de0c"><enum>(I)</enum><text>are identified on 1 or more disclaimers under section 253 to obviate obviousness-type double patenting of another commonly owned patent; or</text></subclause><subclause commented="no" display-inline="no-display-inline" indent="up1" id="id7736918e715543dd9921c6793224d0d9"><enum>(II)</enum><text>are subject to 1 or more disclaimers under section 253 to obviate obviousness-type double patenting of another commonly owned patent.</text></subclause></clause><clause commented="no" display-inline="no-display-inline" indent="up1" id="id5b416e354e4742e6b5fdde2460a965a3"><enum>(ii)</enum><text>For purposes of clause (i)(I)—</text><subclause commented="no" display-inline="no-display-inline" id="id5810736926a843ac8a1dfe9a315a963a"><enum>(I)</enum><text display-inline="yes-display-inline">each patent or application that identifies the same patent or application on a disclaimer under section 253 is part of the same Patent Group; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id55da4e6d6a684b428f14e6a2a6040041"><enum>(II)</enum><text>each patent or application that is identified on a disclaimer under section 253 is part of the same Patent Group as the patent or application subject to the disclaimer.</text></subclause></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="ide9e9cdac5ebc476a936b092125e76893"><enum>(b)</enum><header>Applicability</header><text>The amendment made by subsection (a) shall apply with respect to an application submitted under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>) on or after the date of enactment of this Act.</text></subsection></section></legis-body></bill> 

